Financials
- Market Capitalization 2.13 B
- Employee 291
- Founded 2004
- CEO N/A
- Website www.urogen.com
- Headquarter Israel
- FIGI N/A
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 1941 | SRPT Sarepta Therapeutics, Inc. - Common Stock | 20.86 USD | -3.38% | +12.39% | +34.58% | +15.57% | 2.20 B USD | ||
| 1948 | AUPH Aurinia Pharmaceuticals Inc - Common Shares | 16.29 USD | -1.15% | -1.69% | +10.07% | +36.55% | 2.17 B USD | ||
| 1972 | VCEL Vericel Corporation - Common Stock | 40.95 USD | -0.56% | -4.05% | -12.82% | +12.65% | 2.10 B USD | ||
| 1975 | ADMA ADMA Biologics Inc - Common Stock | 9.34 USD | -1.48% | -4.69% | +8.73% | -45.35% | 2.09 B USD |
Frequently asked questions about UroGen Pharma Ltd. Ordinary Shares
What is the UroGen Pharma Ltd. Ordinary Shares stock price today?
The current price of UroGen Pharma Ltd. Ordinary Shares (URGN) is 43.62. Over the past 24 hours, the stock has changed by -4.13%. Follow the URGN chart for real-time price dynamics.
What is the stock ticker of UroGen Pharma Ltd. Ordinary Shares?
UroGen Pharma Ltd. Ordinary Shares trades under the ticker URGN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is UroGen Pharma Ltd. Ordinary Shares stock going up?
URGN has changed by -6.76% over the last week, +6.13% over the last month, and +129.58% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of UroGen Pharma Ltd. Ordinary Shares?
UroGen Pharma Ltd. Ordinary Shares currently has a market capitalization of 2.13 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were UroGen Pharma Ltd. Ordinary Shares earnings last quarter?
Last quarter, UroGen Pharma Ltd. Ordinary Shares reported earnings of -0.28 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was UroGen Pharma Ltd. Ordinary Shares revenue for the last quarter?
UroGen Pharma Ltd. Ordinary Shares reported quarterly revenue of 67.57 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was UroGen Pharma Ltd. Ordinary Shares net income for the last quarter?
UroGen Pharma Ltd. Ordinary Shares reported net income of -14.35 M for the last quarter. The previous quarter showed -23.57 M, which means net income changed by +39.12%.
How many employees does UroGen Pharma Ltd. Ordinary Shares have?
As of the latest available data, UroGen Pharma Ltd. Ordinary Shares has 291 employees. Workforce size can provide additional context about the company's scale and operations.
What is UroGen Pharma Ltd. Ordinary Shares EBITDA?
UroGen Pharma Ltd. Ordinary Shares EBITDA is -5.12 M, and its EBITDA margin is -7.57%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy UroGen Pharma Ltd. Ordinary Shares stock?
You can buy UroGen Pharma Ltd. Ordinary Shares (URGN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in UroGen Pharma Ltd. Ordinary Shares stock?
Investing in UroGen Pharma Ltd. Ordinary Shares requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the URGN chart and related analysis on metatrader.com as part of your research.